Description
Molsun (Molnupiravir) 400 mg
Molsun 400 mg is identified as a molnupiravir-containing medicine. Molnupiravir is an oral antiviral used for COVID-19 treatment in adults at high risk of progression to severe disease, where authorised or approved locally. Official sources describe it as an unapproved or authorised medicine depending on jurisdiction and regulatory status.
Active Ingredient and Medicine Class
The verified active ingredient is molnupiravir. It is a direct-acting antiviral and a ribonucleoside analogue prodrug. After activation in the body, it interferes with replication of SARS-CoV-2, the virus that causes COVID-19.
Established Medical Uses
Regulatory sources describe molnupiravir for the treatment of mild-to-moderate COVID-19 in adults who are at high risk of severe outcomes, including hospitalisation or death, when other authorised or approved options are not accessible or clinically appropriate. It is not authorised for initiation in patients hospitalised because of COVID-19, and benefit has not been shown when started after hospitalisation.
How It Works
Molnupiravir is converted in the body to an active form that is incorporated into viral RNA. This leads to accumulation of copying errors during viral replication, reducing the virus’s ability to multiply.
Important Safety Information
Official prescribing information states that no formal contraindications have been identified from the limited available data, but important precautions remain. Use is not recommended during pregnancy because of embryo-fetal toxicity concerns, and it is not authorised in patients under 18 years because of potential effects on bone and cartilage growth. Hypersensitivity reactions, including anaphylaxis, have been reported. No clinically significant drug interactions have been identified in the authorised information, but data are limited.
Possible Side Effects
Commonly reported adverse effects include diarrhoea, nausea and dizziness. Less common but important reactions include hypersensitivity, angioedema and anaphylaxis. Vomiting has also been reported after authorisation.
Scientific Evidence
In the phase 3 MOVe-OUT trial, molnupiravir was studied in non-hospitalised adults with mild-to-moderate COVID-19 and risk factors for severe disease. Peer-reviewed evidence and later systematic reviews suggest possible benefits in some high-risk outpatient settings, but overall clinical effects are modest and vary by study population and outcome. Reviews published in PubMed also note little to no difference in serious adverse events compared with placebo or usual care in the analysed trials.
Medical Information Notice
This educational summary is based on sources available at the time of review and does not replace the official patient leaflet, local prescribing information, or individual assessment by a qualified healthcare professional.
Medical Sources
- FDA / DailyMed — LAGEVRIO (molnupiravir) capsule, prescribing information and emergency use fact sheet: DailyMed
- U.S. Food and Drug Administration — Emergency Use Authorization for Molnupiravir 200 mg Capsules: FDA
- Jayk Bernal A, et al. “Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.” New England Journal of Medicine, 2021. PubMed
